Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory

2010 Volkow, 2014, Medication-assisted therapies—tackling the opioid-overdose epidemic, N Engl J Med, 370, 2063, 10.1056/NEJMp1402780 Cernasev, 2021, A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder, Explor Res Clin Soc Pharm, 2 Stringer, 2021, Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder, J Subst Abuse Treat, 123, 10.1016/j.jsat.2020.108263 Radfar, 2021, Reorganization of substance use treatment and harm reduction services during the COVID-19 pandemic: a global survey, Front Psychiatry, 12, 10.3389/fpsyt.2021.639393 Ostrach, 2020, COVID-19 and rural harm reduction challenges in the US southern mountains, J Rural Health, 37, 252, 10.1111/jrh.12499 Ali, 2021, Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada, Int J Drug Policy, 93, 10.1016/j.drugpo.2021.103237 Chang, 2020, COVID-19—enacting a ‘new normal’ for people who use drugs, Int J Drug Policy, 83, 10.1016/j.drugpo.2020.102832 Imtiaz, 2021, The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data, Subst Abuse Treat Prev Policy, 16, 87, 10.1186/s13011-021-00423-5 Friedman, 2022, Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic, JAMA Psychiatry, 79, 379, 10.1001/jamapsychiatry.2022.0004 Farhoudian, 2020, COVID-19 and substance use disorders: recommendations to a comprehensive healthcare response. An International Society of Addiction Medicine practice and policy interest group position paper, Basic Clin Neurosci, 11, 133 Cole, 2021, Patient satisfaction with medications for opioid use disorder treatment via telemedicine: brief literature review and development of a new assessment, Front Public Health, 8, 10.3389/fpubh.2020.557275 Watson, 2021, Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial, BMC Public Health, 21, 630, 10.1186/s12889-021-10669-0 Harris, 2020, Low barrier tele-buprenorphine in the time of COVID-19: a case report, J Addict Med, 14, e136, 10.1097/ADM.0000000000000682 Uscher-Pines, 2020, Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine, J Subst Abuse Treat, 118, 10.1016/j.jsat.2020.108124 Mofizul Islam, 2013, Defining a service for people who use drugs as ‘low-threshold’: what should be the criteria?, Int J Drug Policy, 24, 220, 10.1016/j.drugpo.2013.03.005 Schroeder, 2022, Understanding implementation context and social processes through integrating Normalization Process Theory (NPT) and the Consolidated Framework for Implementation Research (CFIR), Implement Sci Commun, 3, 13, 10.1186/s43058-022-00264-8 Wensing, 2020, Implementation science in times of Covid-19, Implement Sci, 15, 42, 10.1186/s13012-020-01006-x Huddlestone, 2020, Application of normalisation process theory in understanding implementation processes in primary care settings in the UK: a systematic review, BMC Fam Pract, 21, 52, 10.1186/s12875-020-01107-y Grant, 2009, A typology of reviews: an analysis of 14 review types and associated methodologies, Health Info Libr J, 26, 91, 10.1111/j.1471-1842.2009.00848.x Peters, 2020, Chapter 11: scoping reviews Tricco, 2018, PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation, Ann Intern Med, 169, 467, 10.7326/M18-0850 Ouzzani, 2016, Rayyan—a web and mobile app for systematic reviews, Syst Rev, 5, 210, 10.1186/s13643-016-0384-4 Thomas, 2008, Methods for the thematic synthesis of qualitative research in systematic reviews, BMC Med Res Methodol, 8, 45, 10.1186/1471-2288-8-45 Lin, 2019, Telemedicine-delivered treatment interventions for substance use disorders: a systematic review, J Subst Abuse Treat, 101, 38, 10.1016/j.jsat.2019.03.007 Eibl, 2017, The state of opioid agonist therapy in Canada 20 years after federal oversight, Can J Psychiatry, 62, 444, 10.1177/0706743717711167 Young, 2012, Telemedicine interventions for substance-use disorder: a literature review, J Telemed Telecare, 18, 47, 10.1258/jtt.2011.110608 Alexander, 2021, The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review, Subst Abuse Treat Prev Policy, 16, 60, 10.1186/s13011-021-00395-6 Chan, 2021, Opioid treatment programs, telemedicine and COVID-19: a scoping review, Substance Abuse, 43, 539, 10.1080/08897077.2021.1967836 Guillen, 2021, Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review, Telemed J E Health, 28, 761 Krawczyk, 2021, Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review, Addict Sci Clin Pract, 16, 68, 10.1186/s13722-021-00275-1 Eibl, 2017, The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting, Drug Alcohol Depend, 176, 133, 10.1016/j.drugalcdep.2017.01.048 Textor, 2022, ‘Red flags’ and ‘red tape’: telehealth and pharmacy-level barriers to buprenorphine in the United States, Int J Drug Policy, 105, 10.1016/j.drugpo.2022.103703 Castillo, 2020, Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic, Harm Reduct J, 17, 88, 10.1186/s12954-020-00438-4 Duncan, 2021, Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic, J Subst Abuse Treat, 121, 10.1016/j.jsat.2020.108161 Fiacco, 2021, Telemedicine works for treating substance use disorder: the STAR clinic experience during COVID-19, J Subst Abuse Treat, 125, 10.1016/j.jsat.2021.108312 Ghosh, 2021, Telemedicine-assisted stepwise approach of service delivery for substance use disorders in India, Asian J Psychiatr, 58, 10.1016/j.ajp.2021.102582 Harris, 2022, Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program, Drug Alcohol Depend, 230, 10.1016/j.drugalcdep.2021.109187 Levander, 2021, Low-threshold buprenorphine via community partnerships and telemedicine—case reports of expanding access to addiction treatment during COVID-19, J Addict Med, 16, e56, 10.1097/ADM.0000000000000811 Mansour, 2021, Telemedicine and office-based care for behavioral and psychiatric conditions during the covid-19 pandemic in the United States, Ann Intern Med, 174, 428, 10.7326/M20-6243 McIntyre, 2018, Combatting the opioid crisis from prison: initiating opioid agonist therapy, J Forensic Nurs, 14, 248, 10.1097/JFN.0000000000000221 Tofighi, 2021, A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system's initiative to expand treatment access during the COVID-19 pandemic, J Addict Med, 16, e40, 10.1097/ADM.0000000000000809 Tringale, 2021, COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange, J Subst Abuse Treat, 121, 10.1016/j.jsat.2020.108181 Aronowitz, 2021, Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives, Harm Reduct J, 18, 119, 10.1186/s12954-021-00572-7 Eaves, 2020, Another silver lining?: Anthropological perspectives on the promise and practice of relaxed restrictions for telemedicine and medication-assisted treatment in the context of COVID-19, Hum Organ, 79, 292, 10.17730/1938-3525-79.4.292 Mattocks, 2022, Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic, J Subst Abuse Treat, 139, 10.1016/j.jsat.2022.108777 Walters, 2022, Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities, Subst Use Misuse, 57, 1144, 10.1080/10826084.2022.2064509 Cales, 2022, The COVID-19 pandemic and opioid use disorder: expanding treatment with buprenorphine, and combining safety precautions with telehealth, J Subst Abuse Treat, 133, 10.1016/j.jsat.2021.108543 Caton, 2021, COVID-19 adaptations in the care of patients with opioid use disorder: a survey of California primary care clinics, J Gen Intern Med, 36, 998, 10.1007/s11606-020-06436-3 Jones, 2021, Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic, Drug Alcohol Depend, 225, 10.1016/j.drugalcdep.2021.108783 Lambdin, 2022, Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States, Drug Alcohol Depend, 237, 10.1016/j.drugalcdep.2022.109504 Avalone, 2022, Increased attendance during rapid implementation of telehealth for substance use disorders during COVID-19 at the largest public hospital system in the United States, Subst Use Misuse, 57, 1322, 10.1080/10826084.2022.2079140 Cunningham, 2022, A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic, J Subst Abuse Treat, 135, 10.1016/j.jsat.2021.108641 Day, 2022, Virtual opioid agonist treatment: Alberta's virtual opioid dependency program and outcomes, Addict Sci Clin Pract, 17, 40, 10.1186/s13722-022-00323-4 Huskamp, 2018, How is telemedicine being used in opioid and other substance use disorder treatment?, Health Aff, 37, 1940, 10.1377/hlthaff.2018.05134 Kaur, 2022, Impact of telemedicine on retention in medications for opioid use disorder (MOUD) treatment with buprenorphine in the times of COVID-19 pandemic: a retrospective chart review, Rural Mental Health, 46, 75, 10.1037/rmh0000206 LaBelle, 2018, Characterizing the use of telepsychiatry for patients with opioid use disorder and cooccurring mental health disorders in Ontario, Canada, Int J Telemed Appl, 2018 Lambdin, 2022, Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs, Subst Abuse Treat Prev Policy, 17, 51, 10.1186/s13011-022-00483-1 Weintraub, 2021, Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review, Heroin Addict Relat Clin Probl, 23, 5 Zheng, 2017, Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis, J Addict Med, 11, 138, 10.1097/ADM.0000000000000287 Cavazos-Rehg, 2020, Delivering information about medication assisted treatment to individuals who misuse opioids through a mobile app: a pilot study, J Public Health, 42, 149, 10.1093/pubmed/fdy207 Guille, 2020, Treatment of opioid use disorder in pregnant women via telemedicine: a nonrandomized controlled trial, JAMA Netw Open, 3, 10.1001/jamanetworkopen.2019.20177 Gustafson, 2016, The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial, Trials, 17, 592, 10.1186/s13063-016-1726-1 Schramm, 2020, Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial, Addict Sci Clin Pract, 15, 30, 10.1186/s13722-020-00203-9 Treloar, 2021, Telemedicine in addictions feasibility RCT—staff and patient qualitative satisfaction, BJPsych Open, 7, S297, 10.1192/bjo.2021.786 Brunet, 2020, Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine, Substance Abuse, 43, 39, 10.1080/08897077.2020.1728466 Tofighi, 2015, Mobile phone use patterns and preferences in safety net office-based buprenorphine patients, J Addict Med, 9, 217, 10.1097/ADM.0000000000000121 Weintraub, 2018, Expanding access to buprenorphine treatment in rural areas with the use of telemedicine, Am J Addict, 27, 612, 10.1111/ajad.12805 Lingam, 2019, Teleprescribing controlled substances: flowchart analysis of the Ryan Haight Act and state telemedicine laws, J Technol Behav Sci, 4, 346, 10.1007/s41347-019-00100-2 Coulter, 2020, Establishing a telehealth program in primary care for the treatment of opioid use disorder, J Dr Nurs Pract, 13, 207 Crowley, 2020, A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report, Harm Reduct J, 17, 49, 10.1186/s12954-020-00394-z Moore, 2021, Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program, J Addict Nurs, 32, 205, 10.1097/JAN.0000000000000419 Hser, 2021, Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network trial, Addict Sci Clin Pract, 16, 24, 10.1186/s13722-021-00233-x Lin, 2022, Comparing telemedicine to in-person buprenorphine treatment in US veterans with opioid use disorder, J Subst Abuse Treat, 133, 10.1016/j.jsat.2021.108492 O'Gurek, 2021, Designing and evaluating COVID-19 protocols for an office-based opioid treatment program in an urban underserved setting, J Am Board Fam Med, 34, S136, 10.3122/jabfm.2021.S1.200207 Durand, 2022, Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study, Int J Drug Policy, 106, 10.1016/j.drugpo.2022.103768 Tofighi, 2022, Outcomes of a NYC public hospital system low-threshold tele-buprenorphine bridge clinic at 1 year, Subst Use Misuse, 57, 1337, 10.1080/10826084.2022.2069269 Oesterle, 2020, Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook, Mayo Clin Proc, 95, 2709, 10.1016/j.mayocp.2020.10.011 Garvin, 2021, Use of video telehealth tablets to increase access for veterans experiencing homelessness, J Gen Intern Med, 36, 2274, 10.1007/s11606-021-06900-8 Braithwaite, 2018, When complexity science meets implementation science: a theoretical and empirical analysis of systems change, BMC Med, 16, 63, 10.1186/s12916-018-1057-z Samuels, 2020, Innovation during COVID-19: improving addiction treatment access, J Addict Med, 14, e8, 10.1097/ADM.0000000000000685 Lee, 2021, Opportunities and challenges for contactless healthcare services in the post-COVID-19 era, Technol Forecast Soc Change, 167, 10.1016/j.techfore.2021.120712 de Brún, 2017, Using Participatory Learning & Action (PLA) research techniques for inter-stakeholder dialogue in primary healthcare: an analysis of stakeholders' experiences, Res Involv Engagem, 3, 28, 10.1186/s40900-017-0077-8 Braithwaite, 2018, Changing how we think about healthcare improvement, BMJ, 361 Neill, 2009, A positive approach to risk requires person-centred thinking, Tizard learning disability review, 14, 17, 10.1108/13595474200900034